End-of-day quote
Shanghai S.E.
03:30:00 13/05/2024 am IST
|
5-day change
|
1st Jan Change
|
12.97
CNY
|
+0.46%
|
|
+3.43%
|
+4.34%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
20,059
|
26,868
|
24,015
|
21,061
|
23,173
|
24,210
|
-
|
-
|
Enterprise Value (EV)
1 |
20,059
|
26,868
|
24,015
|
21,061
|
23,173
|
24,210
|
24,210
|
24,210
|
P/E ratio
|
22.5
x
|
24.3
x
|
18.7
x
|
14.3
x
|
16.4
x
|
15.9
x
|
13.8
x
|
12.2
x
|
Yield
|
1.55%
|
1.08%
|
1.17%
|
1.59%
|
1.45%
|
1.43%
|
1.62%
|
1.7%
|
Capitalization / Revenue
|
1.67
x
|
1.99
x
|
1.51
x
|
1.23
x
|
1.39
x
|
1.39
x
|
1.28
x
|
1.21
x
|
EV / Revenue
|
1.67
x
|
1.99
x
|
1.51
x
|
1.23
x
|
1.39
x
|
1.39
x
|
1.28
x
|
1.21
x
|
EV / EBITDA
|
7.3
x
|
7.55
x
|
6.71
x
|
4.91
x
|
5.12
x
|
8.26
x
|
7.05
x
|
6.36
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
1.94
x
|
2.45
x
|
2.05
x
|
1.66
x
|
1.69
x
|
1.62
x
|
1.48
x
|
1.35
x
|
Nbr of stocks (in thousands)
|
19,38,033
|
19,31,529
|
18,70,352
|
18,65,499
|
18,64,280
|
18,66,635
|
-
|
-
|
Reference price
2 |
10.35
|
13.91
|
12.84
|
11.29
|
12.43
|
12.97
|
12.97
|
12.97
|
Announcement Date
|
10/04/20
|
30/03/21
|
30/03/22
|
10/04/23
|
02/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
11,980
|
13,522
|
15,904
|
17,143
|
16,646
|
17,364
|
18,968
|
19,978
|
EBITDA
1 |
2,749
|
3,559
|
3,578
|
4,285
|
4,529
|
2,930
|
3,436
|
3,806
|
EBIT
1 |
2,187
|
2,973
|
2,983
|
3,480
|
3,507
|
3,646
|
4,210
|
4,812
|
Operating Margin
|
18.26%
|
21.99%
|
18.76%
|
20.3%
|
21.07%
|
21%
|
22.2%
|
24.08%
|
Earnings before Tax (EBT)
1 |
2,178
|
2,950
|
2,952
|
3,456
|
3,466
|
3,622
|
4,186
|
4,774
|
Net income
1 |
894.3
|
1,120
|
1,328
|
1,503
|
1,443
|
1,521
|
1,743
|
1,984
|
Net margin
|
7.47%
|
8.29%
|
8.35%
|
8.77%
|
8.67%
|
8.76%
|
9.19%
|
9.93%
|
EPS
2 |
0.4607
|
0.5728
|
0.6858
|
0.7921
|
0.7565
|
0.8133
|
0.9367
|
1.065
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.1600
|
0.1500
|
0.1500
|
0.1800
|
0.1800
|
0.1850
|
0.2100
|
0.2200
|
Announcement Date
|
10/04/20
|
30/03/21
|
30/03/22
|
10/04/23
|
02/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
8.98%
|
10.4%
|
11.5%
|
12.2%
|
11%
|
10.3%
|
10.8%
|
11%
|
ROA (Net income/ Total Assets)
|
-
|
4.18%
|
4.48%
|
4.5%
|
4%
|
5.33%
|
5.57%
|
6.4%
|
Assets
1 |
-
|
26,798
|
29,630
|
33,417
|
36,047
|
28,519
|
31,310
|
30,992
|
Book Value Per Share
2 |
5.340
|
5.680
|
6.250
|
6.800
|
7.370
|
8.010
|
8.750
|
9.600
|
Cash Flow per Share
2 |
1.190
|
1.550
|
1.320
|
2.060
|
2.110
|
2.510
|
2.090
|
2.110
|
Capex
1 |
701
|
781
|
1,512
|
1,145
|
1,115
|
913
|
1,116
|
975
|
Capex / Sales
|
5.85%
|
5.78%
|
9.51%
|
6.68%
|
6.7%
|
5.26%
|
5.88%
|
4.88%
|
Announcement Date
|
10/04/20
|
30/03/21
|
30/03/22
|
10/04/23
|
02/04/24
|
-
|
-
|
-
|
Last Close Price
12.97
CNY Average target price
14.7
CNY Spread / Average Target +13.34% Consensus |
1st Jan change
|
Capi.
|
---|
| +4.34% | 334.75Cr | | +29.98% | 68TCr | | +30.34% | 59TCr | | -3.52% | 36TCr | | +18.59% | 33TCr | | +4.07% | 28TCr | | +16.21% | 24TCr | | +9.66% | 21TCr | | -6.83% | 20TCr | | +7.09% | 17TCr |
Other Pharmaceuticals
|